The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding
J de Leon - Revista de Psiquiatría y Salud Mental (English Edition), 2015 - Elsevier
The literature on inducers in epilepsy and bipolar disorder is seriously contaminated by false
negative findings. Part II of this comprehensive review on antiepileptic drug (AED) inducers …
negative findings. Part II of this comprehensive review on antiepileptic drug (AED) inducers …
Phenotypic Models of Drug–Drug‐Gene Interactions Mediated by Cytochrome Drug‐Metabolizing Enzymes
R Viviani, J Berres, JC Stingl - Clinical Pharmacology & …, 2024 - Wiley Online Library
Genetic polymorphisms in drug metabolizing enzymes and drug–drug interactions are major
sources of inadequate drug exposure and ensuing adverse effects or insufficient responses …
sources of inadequate drug exposure and ensuing adverse effects or insufficient responses …
Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach
M Tod, C Nkoud-Mongo, F Gueyffier - The AAPS journal, 2013 - Springer
Currently, quantitative prediction of the impact of genetic polymorphism and drug-drug
interactions mediated by cytochromes, based on in vivo data, is made by two separate …
interactions mediated by cytochromes, based on in vivo data, is made by two separate …
In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19
In order to quantitatively predict drug interactions associated with efavirenz-based anti-HIV
therapy, we evaluated reversible and time-dependent inhibitions of efavirenz on eight …
therapy, we evaluated reversible and time-dependent inhibitions of efavirenz on eight …
In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates
S Goutelle, L Bourguignon, N Bleyzac, J Berry… - The AAPS journal, 2013 - Springer
We present a unified quantitative approach to predict the in vivo alteration in drug exposure
caused by either cytochrome P450 (CYP) gene polymorphisms or CYP-mediated drug–drug …
caused by either cytochrome P450 (CYP) gene polymorphisms or CYP-mediated drug–drug …
Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype
M Hendset, E Molden, M Knape… - Therapeutic drug …, 2014 - journals.lww.com
Background: Cytochrome P450 2D6 intermediate metabolizer phenotype (CYP2D6 IM)
comprises various genotype subgroups. The aim of this study was to evaluate serum …
comprises various genotype subgroups. The aim of this study was to evaluate serum …
Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure
AC Castellan, M Tod, F Gueyffier, M Audars… - Clinical …, 2013 - Springer
Abstract Background and Objective Cytochrome P450 (CYP) 2C9 is the most common
CYP2C enzyme and makes up approximately onethird of total CYP protein content in the …
CYP2C enzyme and makes up approximately onethird of total CYP protein content in the …
Quantitative prediction of drug interactions caused by CYP1A2 inhibitors and inducers
L Gabriel, M Tod, S Goutelle - Clinical pharmacokinetics, 2016 - Springer
Background A simple method to predict drug–drug interactions mediated by cytochrome
P450 enzymes (CYPs) on the basis of in vivo data has been previously applied for several …
P450 enzymes (CYPs) on the basis of in vivo data has been previously applied for several …
A prediction model of drug exposure in cirrhotic patients according to Child–Pugh classification
J Steelandt, E Jean-Bart, S Goutelle, M Tod - Clinical pharmacokinetics, 2015 - Springer
Abstract Background and Objective Prediction of drug clearance in liver cirrhosis patients is
currently based on in vitro–in vivo extrapolation and physiologically-based pharmacokinetic …
currently based on in vitro–in vivo extrapolation and physiologically-based pharmacokinetic …
Severe CNS depression with duloxetine, ciprofloxacin and CYP2D6 deficiency—role and recognition of drug-drug-gene interactions
M Hoffmann, S Russmann, DF Niedrig - European journal of clinical …, 2022 - Springer
Drug-drug interactions (DDI) as well as pharmacogenetic variants may attenuate
pharmacotherapy's efficacy as well as risks of adverse reactions, yet the relevance of their …
pharmacotherapy's efficacy as well as risks of adverse reactions, yet the relevance of their …